An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma ; volume:16 ; number:1 ; day:11 ; month:8 ; year:2016 ; pages:1-13 ; date:12.2016
BMC cancer ; 16, Heft 1 (11.8.2016), 1-13, 12.2016
- Urheber
-
Nile, Donna L.
- Beteiligte Personen und Organisationen
-
Rae, Colin
Hyndman, Iain J.
Gaze, Mark N.
Mairs, Robert J.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2656-8
- URN
-
urn:nbn:de:1111-2016090922585
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nile, Donna L.
- Rae, Colin
- Hyndman, Iain J.
- Gaze, Mark N.
- Mairs, Robert J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
PARP inhibitors
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Advances and perspectives of PARP inhibitors
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
PARP inhibitors
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Advances and perspectives of PARP inhibitors
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
PARP inhibitors
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Advances and perspectives of PARP inhibitors
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer